Last reviewed · How we verify
Xalacom
At a glance
| Generic name | Xalacom |
|---|---|
| Also known as | Latanoprost 0.005% + Timolol 0.5% preserved eye drops |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of IOP Lowering on Progressive HM (NA)
- Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
- A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). (PHASE3)
- Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
- Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. (PHASE4)
- A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma (PHASE3)
- A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xalacom CI brief — competitive landscape report
- Xalacom updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI